Safety of systemic treatments for Behçet's syndrome. Issue 10 (2nd October 2020)

• Record Type: Journal Article
• Authors: Lopalco, Giuseppe; Rigante, Donato; Lopalco, Antonio; Emmi, Giacomo; Venerito, Vincenzo; Vitale, Antonio; Capozio, Giovanna; Denora, Nunzio; Cantarini, Luca; Iannone, Florenzo
• Is Part Of: Expert opinion on drug safety. Volume 19:Issue 10(2020)
• Page Start: 1269
• Page End: 1301
• Publication Date: 2020-10-02
• Subjects: Autoinflammatory diseases -- anti-TNF agents -- il-1 inhibitors -- precision medicine -- behçet's disease; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2020.1817379
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction: Treatment of Behçet's syndrome (BS) is aimed at controlling all symptoms of such a complex disorder, ensuring a good quality of life and preventing life-threatening complications. A better understanding of the pathogenic role of different chemokines has improved our knowledge of BS and elicited a more specific use of therapies currently available, minimizing the burden of potential side-effects related to treatment. Areas covered: This work aims to provide a detailed overview of the safety profile for current therapies available in the treatment of BS, focusing on the main side-effects, toxicity and contraindications. Expert opinion: The greatest experience in the management of BS has been achieved with the employment of monoclonal anti-tumor necrosis factor antibodies which have been advocated for BS refractory manifestations. Moreover, interleukin-1 inhibitors have proven to be effective as well as safe, despite escalation of their dosage, especially to manage the most severe and difficult-to-treat ocular manifestations. However, general treatment of BS patients remains awkward as protean clinical features may respond differently to the same treatment or even worsen. Therefore, patients' safety for therapies used in BS promotes the implementation of precision medicine, which could help targeting accurately the pathogenetic mechanisms concealed behind specific clinical phenotypes.